L-NORADRENALIN

StockNo	Product description	Status
EB0280-418-07	L-NORADRENALINE AMPOULE 1 MG/1 ML (0.1%)

 

COMPOSITION:
L-noradrenaline 1 mg/ml in one ampoule

ACTION:
A physiological mediator of adrenergic neurons ensuring a constant vascular tone; it is secreted by the chromaffine cells in the medullar part of the suprarenal glands and postganglionic sympathetic synapses. Its action in connected with its predominant influence on L-adrenoreceptors. Compared to adrenaline, it has a stronger vasoconstrictive and pressor action, but a weaker stimulating effect on cardiac contractions (it does not increase the minute volume and does not slow down the rhythm). Its broncholytic effect and its influence on metabolism are weaker too. The vasoconstrictive effect of Noradrenaline (except on the coronary vessels) is manifested in a marked increase of systolic and diastolic arterial pressure. It ranks first according to pressor activity: before adrenaline, vasoton, effortil but its effect is shorter-lived, due to its quicker inactivation in the digestive tract. It is not absorbed in the subcutaneous connective tissue, but causes necrosis because of its potent vasoconstricitve action.

INDICATIONS:
L-noradrenaline is applied most often in acute circulatory insufficiency - to increase arterial pressure (if sharply decreased as a result of hemorrhage, trauma, intoxications), as well as to stabilise it during surgical interventions on the sympathetic nervous system. It is used for treatment of vascular collapse (but in parallel with infusions of blood or blood substitutes). It is also sometimes added to local anesthetics in adrenaline-sensitive patients.

CONTRAINDICATIONS:
Full AV-block; fluorotane, chloroform and cyclopropane narcosis (because of danger of venticular fibrillations). Manifest forms of atherosclerosis, hypertension, hyperthyreoidism, pregnancy.

SIDE EFFECTS:
Extravascularly, Noradrenaline may cause necrosis (it is injected strictly intravenously in very diluted solution). It provokes bradycardia and a sudden increase of AP values (danger of cerebral hemorrhage in hypersensitive patients).

DRUG INTERACTIONS:
Simultaneous application with atropine may cause a sharp rise in arterial pressure. It enhances the sympathomimetic action of the ganglionic blockers and the tricyclic antidepressants.

DOSAGE AND ADMINISTRATION:
Noradrenaline is applied intravenously in a system with 5 % solution of glucose or saline, calculated so that 1 liter should contain 4-8 mg of the preparation, and administered at a rate of 20-60 drops/min (under constant control of BP). If bradycardia appears, it is eliminated with atropine. The preparation is applied intramuscularly only very rarely, in a dose of 0.5-1 mg. Subcutaenous injection leads to necrosis.

MEDICINAL FORM AND PACKAGE:
Ampoules of 1 mg/1 ml (0.1 %) in packs of 10, 50 and 100.

STORAGE:
At moderate temperature (15-30° C) in a place protected from direct sunlight.

EXPIRY:
1 (one) year.